Nigel Stallard

9.4k total citations
193 papers, 4.4k citations indexed

About

Nigel Stallard is a scholar working on Statistics and Probability, Management Science and Operations Research and Economics and Econometrics. According to data from OpenAlex, Nigel Stallard has authored 193 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Statistics and Probability, 62 papers in Management Science and Operations Research and 49 papers in Economics and Econometrics. Recurrent topics in Nigel Stallard's work include Statistical Methods in Clinical Trials (105 papers), Optimal Experimental Design Methods (60 papers) and Health Systems, Economic Evaluations, Quality of Life (49 papers). Nigel Stallard is often cited by papers focused on Statistical Methods in Clinical Trials (105 papers), Optimal Experimental Design Methods (60 papers) and Health Systems, Economic Evaluations, Quality of Life (49 papers). Nigel Stallard collaborates with scholars based in United Kingdom, Germany and United States. Nigel Stallard's co-authors include Susan Todd, Tim Friede, Nick Parsons, John Whitehead, Thomas Hamborg, Sarah Stewart‐Brown, Peter Kimani, Anne Whitehead, William F. Rosenberger and D. Simkiss and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Nigel Stallard

188 papers receiving 4.3k citations

Peers

Countries citing papers authored by Nigel Stallard

Since Specialization

Citations

This map shows the geographic impact of Nigel Stallard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Stallard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Stallard more than expected).

Fields of papers citing papers by Nigel Stallard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Stallard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Stallard. The network helps show where Nigel Stallard may publish in the future.

Co-authorship network of co-authors of Nigel Stallard

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Stallard. A scholar is included among the top collaborators of Nigel Stallard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Stallard. Nigel Stallard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Silico Clinical Trials in Drug Development: A Systematic Review 2025 ·Therapeutic Innovation & Regulatory Science ·(unknown), (unknown), Christian Röver, Emmanuelle Comets, Markus C. Elze, Andrew C. Hooker, Joanna IntHout, Anne‐Sophie Jannot, Daria Julkowska, (unknown), (unknown), Nigel Stallard, Moreno Ursino, Marc Vandemeulebroecke, Sebastian Weber, Martin Posch, Sarah Zohar, Tim Friede	0
2	Adjusting for treatment selection in phase II/III clinical trials with time to event data 2022 ·Statistics in Medicine ·Jamal Nasir Khan, Peter Kimani, Ekkehard Glimm, Nigel Stallard	1
3	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis 2022 ·Neurology ·Vivien Li, Baptiste Leurent, Frederik Barkhof, Marie Braisher, Fay Cafferty, Olga Ciccarelli, Arman Eshaghi, Emma Gray, Jennifer M. Nicholas, Mahesh Parmar, Guy Peryer, (unknown), Nigel Stallard, James Wason, Jeremy Chataway	12
4	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease 2022 ·BMJ Open ·(unknown), Rachel Dakin, J Williamson, Judith Newton, (unknown), Shuna Colville, Maria Stavrou, Jenna M. Gregory, (unknown), Arpan R. Mehta, Jeremy Chataway, Robert Swingler, Richard Parker, Christopher J. Weir, Nigel Stallard, Mahesh Parmar, Malcolm Macleod, Suvankar Pal, Siddharthan Chandran	18
5	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). 2021 ·Apollo (University of Cambridge) ·(unknown), Karoline Freeman, Karen Clements, Bridget Hilton, (unknown), Olive Kearins, Nigel Stallard, Matthew Wallis, Nisha Sharma, Cliona Kirwan, Sarah E. Pinder, Elena Provenzano, Abeer M. Shaaban, Hilary Stobart, (unknown), Alastair M. Thompson, Sian Taylor‐Phillips	4
6	Protocol for a randomised controlled trial of Subacromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery (START:REACTS) 2020 ·BMJ Open ·Andrew Metcalfe, Elke Gemperlé Mannion, Helen Parsons, Jaclyn Brown, Nick Parsons, (unknown), Rebecca Kearney, Tom Lawrence, Howard S. Bush, Kerri McGowan, Iftekhar Khan, James Mason, Charles Hutchinson, Simon Gates, Nigel Stallard, Martin Underwood, Steve Drew	10
7	Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R 2020 ·Biometrical Journal ·Tim Friede, Nigel Stallard, Nick Parsons	22
8	Comparison of Bayesian and frequentist group-sequential clinical trial designs 2020 ·BMC Medical Research Methodology ·Nigel Stallard, Susan Todd, Elizabeth Ryan, Simon Gates	33
9	To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework 2019 ·Statistics in Medicine ·(unknown), James Wason, Nigel Stallard	9
10	Approaches to sample size calculation for clinical trials in rare diseases 2018 ·Pharmaceutical Statistics ·Frank Miller, Sarah Zohar, Nigel Stallard, Jason Madan, Martin Posch, Siew Wan Hee, Michael Pearce, Mårten Vågerö, Simon Day	14
11	Recommendations for the design of small population clinical trials 2018 ·Orphanet Journal of Rare Diseases ·Simon Day, Anneliene Hechtelt Jonker, Lilian Pek Lian Lau, R.-D Hilgers, Ilan Irony, Kristina Larsson, Kit CB Roes, Nigel Stallard	73
12	Decision‐theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta‐binomial distribution 2017 ·Biometrical Journal ·Siew Wan Hee, Nick Parsons, Nigel Stallard	2
13	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov 2017 ·Orphanet Journal of Rare Diseases ·Siew Wan Hee, Adrian Willis, Catrin Tudur Smith, Simon Day, Frank Miller, Jason Madan, Martin Posch, Sarah Zohar, Nigel Stallard	38
14	THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MS – CURRENT UPDATE 2016 ·Journal of Neurology Neurosurgery & Psychiatry ·Jeremy Chataway, Siddharthan Chandran, David S. Miller, Peter Connick, Gavin Giovannoni, Sue Pavitt, Nigel Stallard, Clive Hawkins, Basil Sharrack, Domenico Plantone	3
15	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer 2016 ·Health Technology Assessment ·Robert C. Stein, Janet Dunn, John M.S. Bartlett, (unknown), Andrea Marshall, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E. Pinder, David Cameron, Nigel Stallard, Jenny Donovan, Christopher McCabe, Luke Hughes‐Davies, Andreas Makris, (unknown)	55
16	Facet-joint injections for people with persistent non-specific low back pain (FIS): study protocol for a randomised controlled feasibility trial 2015 ·Trials ·Harbinder Sandhu, David R Ellard, Felix Achana, (unknown), (unknown), (unknown), Melinda Cairns, Frances Griffiths, Kirstie Haywood, Charles Hutchinson, Ranjit Lall, Stavros Petrou, Nigel Stallard, Colin Tysall, David A. Walsh, Martin Underwood	5
17	Flexible sequential designs for multi‐arm clinical trials 2014 ·Statistics in Medicine ·Dominic Magirr, Nigel Stallard, Thomas Jaki	23
18	Effectiveness and cost-effectiveness of a universal parenting skills programme in deprived communities: multicentre randomised controlled trial 2013 ·BMJ Open ·D. Simkiss, Helen Snooks, Nigel Stallard, Peter Kimani, Bernadette Sewell, Deborah Fitzsimmons, Rebecca Anthony, (unknown), (unknown), Ceri Phillips, Sarah Stewart‐Brown	32
19	A group‐sequential design for clinical trials with treatment selection 2008 ·Statistics in Medicine ·Nigel Stallard, Tim Friede	81
20	A newly devised scoring system for prediction of mortality in patients with colorectal cancer: a prospective study 2007 ·The Lancet Oncology ·Ali Ferjani, Damian Griffin, Nigel Stallard, Ling S. Wong	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact